$7.18
2.58% yesterday
Nasdaq, Aug 18, 10:00 pm CET
ISIN
US09075A1088
Symbol
BVS

Bioventus Inc - Ordinary Shares - Class A Stock price

$7.18
+0.92 14.70% 1M
-3.21 30.90% 6M
-3.32 31.62% YTD
-0.82 10.25% 1Y
-1.29 15.23% 3Y
-5.82 44.77% 5Y
-5.82 44.77% 10Y
-5.82 44.77% 20Y
Nasdaq, Closing price Mon, Aug 18 2025
-0.19 2.58%

Key metrics

Basic
Market capitalization
$608.5m
Enterprise Value
$941.9m
Net debt
$318.4m
Cash
$32.9m
Shares outstanding
82.7m
Valuation (TTM | estimate)
P/E
negative | 10.3
P/S
1.1 | 1.1
EV/Sales
1.7 | 1.6
EV/FCF
27.6
P/B
4.1
Financial Health
Equity Ratio
20.3%
Return on Equity
-22.7%
ROCE
7.7%
ROIC
0.6%
Debt/Equity
2.2
Financials (TTM | estimate)
Revenue
$564.1m | $571.0m
EBITDA
$47.0m | $111.8m
EBIT
$40.1m | $104.8m
Net Income
$-160.0k | -
Free Cash Flow
$34.1m
Growth (TTM | estimate)
Revenue
5.1% | -0.4%
EBITDA
112.2% | 246.3%
EBIT
188.2% | 325.6%
Net Income
99.6% | -
Free Cash Flow
304.0%
Margin (TTM | estimate)
Gross
67.6%
EBITDA
8.3% | 19.6%
EBIT
7.1%
Net
0.0% | -
Free Cash Flow
6.0%
More
EPS
$0.0
FCF per Share
$0.4
Short interest
7.0%
Employees
950
Rev per Employee
$600.0k
Show more

Is Bioventus Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Bioventus Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Bioventus Inc - Ordinary Shares - Class A forecast:

Buy
75%
Hold
25%

Financial data from Bioventus Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
564 564
5% 5%
100%
- Direct Costs 183 183
2% 2%
32%
381 381
7% 7%
68%
- Selling and Administrative Expenses 320 320
0% 0%
57%
- Research and Development Expense 13 13
3% 3%
2%
47 47
112% 112%
8%
- Depreciation and Amortization 6.87 6.87
16% 16%
1%
EBIT (Operating Income) EBIT 40 40
188% 188%
7%
Net Profit -0.16 -0.16
100% 100%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Bioventus Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bioventus Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
11 days ago
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Tuesday, August 12, 2025, at 2:00 p.m. ET.
Neutral
Seeking Alpha
12 days ago
Bioventus Inc. (NASDAQ:BVS ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Crawford - Vice President of Investor Relations & Treasurer Mark L. Singleton - Senior VP & CFO Robert E.
Neutral
GlobeNewsWire
13 days ago
DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 28, 2025.
More Bioventus Inc - Ordinary Shares - Class A News

Company Profile

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from a array of musculoskeletal conditions. It operates through four segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on December 22, 2015 and is headquartered in Durham, NC.

Head office United States
CEO Robert Claypoole
Employees 950
Founded 2011
Website www.bioventus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today